The company received full FDA approval for its drug IMDELLTRA for a specific type of lung cancer, and it was listed as the only preferred treatment option in updated national cancer guidelines. This follows strong Phase 3 trial results showing the drug extended patient survival. The company was also recognized with a patent award for a sustainable biomanufacturing technology. Analysts highlight the company's strong product strength and are bullish on its growth potential, despite the stock underperforming the broader Nasdaq index over the past year.